Low Desire, or a Relationship Problem? How HSDD Is Actually Defined

There is a question underneath a lot of searching about low sexual desire, and it is rarely asked directly: is this a medical problem, or is this about my relationship?

It turns out that diagnostic manuals and drug labels both answer it explicitly — and they draw the line in the same place. Understanding where that line sits is more useful than most of what is written about low desire, because it determines what kind of help is likely to be relevant.

The Short Answer

Distress is necessary for a sexual difficulty to meet diagnostic criteria — but distress alone is not enough. Duration, the pattern of symptoms, and whether something else better explains the change all matter too.

The scale of the distress filter is still striking. In a national survey of 31,581 US women, 43.1% reported a sexual problem, but only 12.0% reported a sexual problem that distressed them.

And relationship distress is an explicit exclusion, not a qualifier. The diagnostic criteria require that the difficulty is not better explained by a non-sexual mental disorder, by severe relationship distress, or by other significant stressors.

Both FDA-approved medications for low desire in women repeat this. Their indications cover low desire causing "marked distress or interpersonal difficulty" — and explicitly exclude low desire that is due to "problems with the relationship."

So the line is not about whether a relationship is affected. It is about what best explains the change.

Low Desire Is Common. Distressing Low Desire Is Much Less So.

The largest US survey of this question, published in Obstetrics & Gynecology in 2008, sampled 31,581 women aged 18 and over from a nationally representative panel.

• Any sexual problem: 43.1%
• Sexually related personal distress: 22.2%
• Any distressing sexual problem — reporting both: 12.0%

Distressing problems peaked in middle age: 14.8% among women aged 45–64, against 10.8% in younger and 8.9% in older women.

The researchers' own conclusion is the line worth keeping: the prevalence of distressing sexual problems "was considerably lower than the prevalence of sexual problems."

Put another way: the prevalence of sexual problems was more than three times the prevalence of sexual problems accompanied by distress. That is not a failure of measurement — it reflects something real. Desire changes across a life, and change is not automatically a disorder.

The desire-specific figure, and what depression does to it

Those headline numbers cover sexual problems of all kinds. A later analysis of the same survey, published in the Journal of Clinical Psychiatry in 2009, re-estimated them for desire specifically — and then asked what happened when concurrent depression was taken into account.

• Distressing desire disorder, unadjusted: 10.0%
• Among women without concurrent depression: 6.3%
• Leaving 3.7% with both conditions present

The authors concluded that around 40% of women with a distressing desire, arousal or orgasm problem had concurrent depression. They were careful about what that does and does not show: the study was cross-sectional, so "causality versus comorbidity cannot be determined." What it does establish is that low desire cannot be interpreted without looking at what else is going on — which is exactly what the diagnostic criteria require.

What the Diagnostic Criteria Require

The current diagnostic manual, DSM-5-TR, does not use "hypoactive sexual desire disorder" for women. It retains the diagnosis introduced in DSM-5 in 2013, which merged the older desire and arousal categories into a single condition: female sexual interest/arousal disorder.

Its criteria have four parts, and each one narrows the definition considerably. In summary rather than in the manual's own words:

A. A pattern, not a single symptom. The diagnosis requires at least three of six persistent reductions, spanning interest in sexual activity, erotic thoughts or fantasies, initiation and receptivity, excitement or pleasure during sex, responsiveness to sexual or erotic cues, and genital or non-genital sensations. Reduced interest on its own does not meet it.

B. Duration. Those symptoms must have persisted for roughly six months. A difficult few weeks does not meet the definition.

C. Distress. The symptoms must cause clinically significant distress to the individual. The FDA labels for the two approved medications use somewhat broader wording — "marked distress or interpersonal difficulty" — but under either framework, a partner's dissatisfaction on its own is not enough to establish the condition.

D. The exclusions. This is the criterion that answers the question in the title. The difficulty must not be better explained by a non-sexual mental disorder, by severe relationship distress or another significant stressor, and must not be attributable to a substance, a medication or another medical condition.

Read together, those four requirements exclude a great deal: brief changes, changes that do not trouble the person experiencing them, changes a partner minds more than she does, and changes better accounted for by a relationship in serious difficulty or by a major life stressor.

DSM-5-TR and Sexual-Medicine Specialists Use Different Frameworks

This is worth knowing, because it explains why the terminology a reader encounters is inconsistent.

In 2016 the International Society for the Study of Women's Sexual Health published a consensus nomenclature that retained hypoactive sexual desire disorder as a standalone clinical diagnosis, rather than adopting the DSM merger of desire and arousal as the only useful framework. Its stated reason: current DSM-5 definitions "do not identify all sexual problems experienced clinically by women and are not necessarily applicable for biologic or biopsychosocial management of female sexual dysfunction."

That is not the same as the field rejecting DSM-5. Two overlapping diagnostic traditions are in use, and the debate about how much daylight there really is between them is live. A 2018 study in the Journal of Sex Research tested the common objection that the newer criteria set the bar too high: among 151 women, 73.5% of those diagnosed with HSDD also met the criteria for sexual interest/arousal disorder, and the authors concluded that the newer criteria "does not unduly raise the bar for diagnosis." Women who met only the older criteria tended to have milder symptoms.

The practical consequence for a reader is simply this: a woman may be told she has HSDD by a sexual-medicine specialist while the current psychiatric manual would file the same presentation under a different name. Neither is wrong; they are different classification systems built for different purposes.

Why the Drug Labels Still Say HSDD

Both FDA-approved treatments for low desire in women use the older term. Their indications cover "acquired, generalized hypoactive sexual desire disorder."

That wording — acquired, generalized — comes from the earlier DSM-IV-TR, and HSDD research still uses those criteria; a 2022 study in the Journal of Clinical Investigation recruited participants using DSM-IV-TR criteria explicitly.

We could not find a published FDA rationale for the choice, so we report the discrepancy rather than explain it. The labels themselves never mention the DSM at all.

The two terms in that phrase are defined on the labels and are useful in their own right:

• Acquired — the difficulty developed in someone who previously had no problem with desire. Lifelong low desire is a different situation.
• Generalized — it occurs regardless of the type of stimulation, the situation, or the partner. Not only with one person, or only in certain circumstances.

That second one does a lot of work. Low desire limited to a particular partner or situation would not fit the "generalized" form the labels specify — though that alone does not establish what is causing the difficulty, and it is not a self-test. Human desire is more complicated than a single distinguishing question.

Mismatched Desire Is Not, By Itself, a Disorder

Nothing in either the diagnostic criteria or the drug indications describes a difference between partners as a condition.

The criteria are about one person's experience, and specifically about whether she is distressed. Criterion C requires clinically significant distress in the individual. A partner's dissatisfaction does not substitute for it.

This matters practically. Two people can want sex at different frequencies without either of them having anything wrong with them. A desire discrepancy between partners is not itself a diagnosis — though either partner could still have an individual sexual disorder, which would require that person's own symptoms, distress, duration and clinical context to meet the criteria. The discrepancy and the diagnosis are separate questions.

And where the sexual difficulty is better explained by severe relationship distress, criterion D places it outside the diagnosis entirely. Neither Addyi nor Vyleesi is FDA-indicated to treat low desire that is due to relationship problems.

None of that makes the difficulty less real or less worth addressing. It changes what kind of help fits. Relationship difficulty is something couples therapists and sex therapists work with, and a treatment approved for a desire disorder is not a substitute for that.

The Real Question Is What Best Explains the Change

It is tempting to reduce this to a chronology test — which came first, the low desire or the relationship trouble? That is not quite what the criteria ask, and the simpler version misleads.

Low desire can strain a relationship, and relationship distress can reduce desire. The two feed each other, and by the time someone is looking for answers both are usually true. A relationship problem can start first without fully explaining the low desire; low desire can start first and later become tangled up with serious relationship distress.

So the diagnostic question is not simply which appeared first. It is whether the sexual difficulty is better explained by severe relationship distress — or whether the relationship difficulty is occurring alongside, or partly because of, a broader and persistent desire problem.

Relationship distress is also not the only alternative explanation. The same criteria exclude low desire better accounted for by another medical condition, a medication, a mental disorder or a major stressor — and that covers a lot of ground. Medical conditions, psychiatric symptoms, medications, pain, sleep disruption and significant life stressors can all be relevant, which is precisely why both diagnostic frameworks require alternative explanations to be considered. Related reading: Low Libido in Women: Causes, HSDD and Treatment Options and Testosterone for Women and Libido: What the Evidence Says.

Sorting between those possibilities is what a clinical assessment is for. A licensed provider can take a detailed history, review medications and health conditions, decide whether any targeted testing is appropriate, and ask the questions that separate one explanation from another. Where the difficulty is relational, a qualified sex or couples therapist is the appropriate referral.

What no article can do — including this one — is tell an individual which situation she is in.

Frequently Asked Questions

What is HSDD?

HSDD is the term retained in sexual-medicine practice and used in FDA labelling for acquired, generalized low sexual desire associated with marked distress or interpersonal difficulty, once other explanations — another medical or psychiatric condition, a relationship problem, or the effects of a medication — have been excluded. Both FDA-approved treatments for low desire in women use that definition on their labels. DSM-5-TR instead classifies female desire and arousal difficulties under female sexual interest/arousal disorder.

Is low sex drive a medical condition?

Sometimes. Low desire by itself is not automatically a disorder. In a survey of 31,581 US women, 43.1% reported a sexual problem but only 12.0% reported one that distressed them; a later analysis of the same data put distressing desire problems specifically at 10.0%, falling to 6.3% among women without concurrent depression. The diagnostic criteria additionally require symptoms lasting around six months, at least three of six features, and that the difficulty is not better explained by relationship distress, another condition, or a medication.

How do you know if low desire is a relationship problem?

Relationship strain caused by low desire does not automatically exclude a diagnosis. But if the sexual difficulty is better explained by severe relationship distress — or, under the drug labels, is due to relationship problems — that points away from HSDD or FSIAD as the primary explanation. Distinguishing between them is difficult to do alone, partly because the two influence each other, and it is part of what a clinical assessment addresses.

Is mismatched libido in a relationship a disorder?

Not by itself. A desire discrepancy between partners is not a diagnosis. The criteria describe one person's experience and require that she is distressed — a partner's dissatisfaction does not substitute for that. Either partner could still have an individual sexual disorder, but that requires their own symptoms, distress, duration and clinical context to meet the criteria. Where the difference itself causes friction, sex or couples therapy is the field that addresses it.

How long does low desire have to last to be diagnosed?

The DSM-5-TR criteria require symptoms persisting for approximately six months. Both drug labels describe trials that enrolled women with at least six months' duration.

What does "acquired, generalized" mean?

Acquired means the difficulty developed in someone who previously had no problem with desire — as opposed to lifelong low desire. Generalized means it occurs regardless of the type of stimulation, situation or partner, rather than only in specific circumstances or with one person. Both approved medications are indicated only for the acquired, generalized form.

Can a partner's low desire be treated?

The person experiencing it has to be the one distressed by it for the diagnostic criteria to be met, and any treatment decision belongs to her and her provider. A partner's concern is a reason to have a conversation, not a basis for a diagnosis.

Who diagnoses HSDD?

A qualified healthcare professional with experience assessing sexual concerns can evaluate HSDD or FSIAD, through a history covering duration, circumstances, medications, medical conditions, mood and relationship context — because the diagnosis is defined as much by what it excludes as by what it includes. Where relational issues dominate, sex therapists and couples therapists may be part of that assessment and support. It is not self-diagnosable from a symptom list.

AmalfiDuo Sexual Wellness Programs

If low desire is persistent and distressing, you can complete a private online health evaluation. A licensed clinician reviews your health information and determines whether further evaluation or treatment may be appropriate. Relationship-focused concerns may be better addressed with a qualified sex or couples therapist, and a good provider will say so.

Explore Sexual Wellness Programs

A prescription is never guaranteed and may not be appropriate.

References

1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstetrics & Gynecology. 2008;112(5):970–978. PMID 18978095.
2. Weiss J, Steil R, Priebe K, et al. Sexual Dysfunctions in Women with Posttraumatic Stress Disorder Following Childhood Sexual Abuse: Prevalence Rates According to DSM-5 and Clinical Correlates. Archives of Sexual Behavior. 2023;52(8):3365–3378. PMID 37468726. Used here as a published secondary source summarising the DSM-5 criteria for female sexual interest/arousal disorder; the criteria are paraphrased rather than reproduced.
3. Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. Journal of Clinical Psychiatry. 2009;70(12):1698–1706. PMID 20141709.
4. Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions — Part II. Journal of Sexual Medicine. 2016;13(12):1888–1906. PMID 27843072.
5. O'Loughlin JI, Basson R, Brotto LA. Women With Hypoactive Sexual Desire Disorder Versus Sexual Interest/Arousal Disorder: An Empirical Test of Raising the Bar. Journal of Sex Research. 2018;55(6):734–746. PMID 29095039.
6. VYLEESI (bremelanotide) injection — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Section 1.
7. ADDYI (flibanserin) tablets — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Section 1.
8. Thurston L, Hunjan T, Mills EG, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. Journal of Clinical Investigation. 2022;132(19). PMID 36189794.

This article is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. It describes published diagnostic criteria in summary form and the contents of FDA-approved prescribing information; it does not diagnose, and it does not offer relationship or psychological counselling. Low sexual desire has many possible causes, several of which are explicitly excluded from the diagnoses described here, and distinguishing between them requires clinical assessment. AmalfiDuo Journal articles are written by AmalfiDuo Editorial and are not medically reviewed — see our Editorial Policy.